终止重大资产重组！000504突发公告！

Core Viewpoint - *ST生物 has announced the termination of its major asset restructuring plan, which was initially aimed at acquiring a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. The termination was agreed upon by all parties involved after failing to reach a substantial agreement during negotiations [1][3]. Group 1: Termination of Restructuring - The company disclosed the termination of the major asset restructuring plan on January 22, 2026, after multiple negotiations failed to yield an agreement [1][3]. - The restructuring plan was first announced on August 12, 2025, but did not progress to the formal implementation stage [1]. Group 2: Impact on Operations - The termination of the restructuring will not have a significant adverse impact on the company's current operations or financial status [3]. - The company maintains that the termination does not harm the interests of shareholders, particularly minority shareholders [3]. Group 3: Financial Performance Forecast - *ST生物 expects its 2025 revenue to be between 385 million to 425 million yuan, with a significant increase from approximately 130 million yuan in the previous year [3]. - The company forecasts a total profit of 18.5 million to 26.5 million yuan for 2025, with net profit attributable to shareholders expected to be between 28.5 million to 32.5 million yuan [3]. - All financial indicators are projected to show a turnaround, with net profit after excluding non-recurring gains and losses estimated between 8.5 million to 12.5 million yuan [3].